2012 EDUCATIONAL BOOK - American Society of Clinical Oncology

TARGETED THERAPY IN SARCOMA
receptor signaling system in JC virus T antigen-induced primitive neuroectodermal
tumors-medulloblastomas. J Neurovirol. 2002;2:138-147 (suppl).
33. Lassak A, Del Valle L, Peruzzi F, et al. Insulin receptor substrate 1
translocation to the nucleus by the human JC virus T-antigen. J Biol Chem.
2002;277:17231-17238.
34. Sehat B, Tofigh A, Lin Y, et al: SUMOylation mediates the nuclear
translocation and signaling of the IGF-1 receptor. Sci Signal. 2010;3:ra10
35. Gleason BC, Hornick JL. Inflammatory myofibroblastic tumours:
where are we now? J Clin Pathol. 2008;61:428-437.
36. Griffin CA, Hawkins AL, Dvorak C, et al. Recurrent involvement of 2p23
in inflammatory myofibroblastic tumors. Cancer Res. 1999;59:2776-2780.
37. Lawrence B, Perez-Atayde A, Hibbard MK, et al. TPM3-ALK and
TPM4-ALK oncogenes in inflammatory myofibroblastic tumors. Am J Pathol.
2000;157:377-384.
38. Coffin CM, Hornick JL, Fletcher CD. Inflammatory myofibroblastic
tumor: Comparison of clinicopathologic, histologic, and immunohistochemical
features including ALK expression in atypical and aggressive cases. Am J
Surg Pathol. 2007;31:509-520.
39. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming
EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448:561-
566.
40. Janoueix-Lerosey I, Lequin D, Brugieres L, et al. Somatic and germline
activating mutations of the ALK kinase receptor in neuroblastoma. Nature.
2008;455:967-970.
41. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and
outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.
J Clin Oncol. 2009;27:4247-4253.
42. Butrynski JE, D’Adamo DR, Hornick JL, et al. Crizotinib in ALKrearranged
inflammatory myofibroblastic tumor. N Engl J Med. 2010;363:
1727-1733.
43. Sasaki T, Okuda K, Zheng W, et al. The neuroblastoma-associated
F1174L ALK mutation causes resistance to an ALK kinase inhibitor in
ALK-translocated cancers. Cancer Res. 2010;70:10038-10043.
44. Hornick JL, Fletcher CD. PEComa: What do we know so far? Histopathology.
2006;48:75-82.
45. Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for angiomyolipoma
in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl
J Med. 2008;358:140-151.
46 Kenerson H, Folpe AL, Takayama TK, et al. Activation of the mTOR
pathway in sporadic angiomyolipomas and other perivascular epithelioid cell
neoplasms. Hum Pathol. 2007;38:1361-1371.
47. Pan CC, Chung MY, Ng KF, et al. Constant allelic alteration on
chromosome 16p (TSC2 gene) in perivascular epithelioid cell tumour
(PEComa): genetic evidence for the relationship of PEComa with angiomyolipoma.
J Pathol. 2008;214:387-393.
48. Wagner AJ, Malinowska-Kolodziej I, Morgan JA, et al. Clinical activity
of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell
tumors: targeting the pathogenic activation of mTORC1 in tumors. J Clin
Oncol. 2010;28:835-840.
49. Italiano A, Delcambre C, Hostein I, et al. Treatment with the mTOR
inhibitor temsirolimus in patients with malignant PEComa. Ann Oncol.
2010;21:1135-1137.
50. Wolff N, Kabbani W, Bradley T, et al. Sirolimus and temsirolimus for
epithelioid angiomyolipoma. J Clin Oncol. 2010;28:e65-e68.
51. Tiet TD, Hopyan S, Nadesan P, et al. Constitutive hedgehog signaling
in chondrosarcoma up-regulates tumor cell proliferation. Am J Pathol. 2006;
168:321-330.
52. Campbell VT, Nadeson PP, Wang Y, et al. Direct targeting of the
Hedgehog pathway in primary chondrosarcoma xenografts with the Smoothened
inhibitor IPI-926. Presented at: Paper presented at: 102 nd Annual
Meeting of the American Association for Cancer Research; April 2011;
Orlando, FL.
53. Amary MF, Bacsi K, Maggiani F, et al. IDH1 and IDH2 mutations
are frequent events in central chondrosarcoma and central and periosteal
chondromas but not in other mesenchymal tumours. J Pathol. 2011;224:334-343.
657